Printer Friendly

Soligenix awarded US patent for treating IBS with oral beclomethasone dipropionate.

M2 EQUITYBITES-19 May 2010-Soligenix awarded US patent for treating IBS with oral beclomethasone dipropionate(C)2010 M2 COMMUNICATIONS

Late-stage biopharmaceutical company Soligenix Inc (OTCBB:SNGX) has been granted a US patent for the treatment of irritable bowel syndrome (IBS) with oral beclomethasone dipropionate (BDP), the company said today.

The new patent number 7,704,985 is entitled "Treatment of Irritable Bowel Syndrome and Related Bowel Diseases".

Christopher J. Schaber PhD, president and CEO of Soligenix, commented: "There is an increasing awareness that IBS results in part from an inflammatory cascade in the GI tract, which makes it amenable to treatment with topically active steroids such as oral BDP."

He added: "We believe that our oral BDP formulations will have utility in other inflammatory GI diseases as well such as Graft-versus-Host disease (GVHD), radiation enteritis and Crohn's disease."

((Comments on this story may be sent to

COPYRIGHT 2010 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:May 19, 2010
Previous Article:Starbucks names Jeff Hansberry as President, Global Consumer Products and Foodservice.
Next Article:Global Sources posts increased net income of USD2.6m in Q1 2010.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters